Overview

Emisphere is a biopharmaceutical company that focuses on a unique and improved delivery of pharmaceutical compounds, medical foods and dietary supplements using its Eligen® Technology. These molecules and compounds could be currently available or in development. Such molecules are usually delivered by injection; in many cases, their benefits are limited due to poor bioavailability, slow on-set of action or variable absorption. The Eligen® Technology can be applied to the oral route of administration as well as other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal or transdermal. The company's website is: www.emisphere.com.

---

Company Highlights Novo Nordisk A/S is conducting Phase I trial of an oral formulation of their proprietary GLP-1 analogue using Eligen® Technology for the treatment of Type 2 Diabetes Emisphere Technologies, Inc. conducted a clinical trial that demonstrated an oral formulation of B12 using our Eligen® Technology repleted B12 levels in deficient patients Broad product pipeline from pre-clinical to commercially viable opportunities Pharmaceutical and nutritional supplement programs address large target markets

Key Pipeline Products Oral GLP-1 analogues for the treatment of Type 2 Diabetes » Development Partner: Novo Nordisk A/S Oral Eligen® Vitamin B12 – final data from a clinical study conducted by Emisphere demonstrated that its 1000mcg oral Eligen® B12 given to individuals with low B12 levels restored normal B12 serum concentrations

Eligen® Advantages Safety demonstrated in thousands of trial participants over the last 20 years Broadly applicable to diverse group of drug molecules (e.g., proteins, peptides and other poorly absorbed compounds) and nutritional supplements Stand-alone delivery approach does not rely on the addition of agents that can have adverse effects on the intestinal membranes or digestion process (e.g., penetration enhancers or enzyme inhibitors) Versatility of formulation, including oral solutions, tablets and capsules, as well as rectal, inhalation, intravaginal administration Ease of manufacture, as the technology and manufacturing equipment required to produce the Eligen® delivery agent material in commercial quantities is readily available

For further information contact:
Michael R. Garone, Interim CEO and CFO
973.532.8005 or mgarone@emisphere.com

Any statements relating to matters that are not historical facts involve risks and uncertainties. For an explanation of risks and uncertainties that may affect Emisphere’s business please refer to Emisphere's periodic reports on Forms 10K, 10Q and 8K filed with the SEC.